Danaher (NYSE:DHR) SVP Brian Ellis Sells 21,776 Shares of Stock

Danaher Corporation (NYSE:DHR) SVP Brian Ellis sold 21,776 shares of the business’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $219.23, for a total value of $4,773,952.48. Following the completion of the sale, the senior vice president directly owned 14,553 shares of the company’s stock, valued at $3,190,454.19. This represents a 59.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Danaher Stock Performance

Shares of NYSE DHR opened at $221.50 on Friday. The business’s 50-day simple moving average is $205.21 and its 200-day simple moving average is $200.91. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52. Danaher Corporation has a 52 week low of $171.00 and a 52 week high of $258.23. The firm has a market cap of $156.46 billion, a price-to-earnings ratio of 45.67, a P/E/G ratio of 3.28 and a beta of 0.81.

Danaher (NYSE:DHR) last announced its earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The firm had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $6 billion. During the same quarter in the prior year, the business earned $1.71 earnings per share. The company’s revenue was up 4.4% on a year-over-year basis. As a group, equities research analysts expect that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Friday, September 26th were issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend was Friday, September 26th. Danaher’s dividend payout ratio is currently 26.39%.

Hedge Funds Weigh In On Danaher

Several large investors have recently added to or reduced their stakes in the company. Perbak Capital Partners LLP lifted its position in shares of Danaher by 75.5% in the 3rd quarter. Perbak Capital Partners LLP now owns 18,112 shares of the conglomerate’s stock worth $3,591,000 after acquiring an additional 7,794 shares during the period. Glenmede Investment Management LP raised its stake in shares of Danaher by 23.5% in the third quarter. Glenmede Investment Management LP now owns 83,802 shares of the conglomerate’s stock valued at $16,615,000 after purchasing an additional 15,945 shares in the last quarter. Banco BTG Pactual S.A. bought a new position in Danaher in the third quarter worth $225,000. Compass Capital Management Inc. boosted its stake in Danaher by 2.3% during the third quarter. Compass Capital Management Inc. now owns 287,737 shares of the conglomerate’s stock worth $57,047,000 after buying an additional 6,481 shares in the last quarter. Finally, Legacy Advisors LLC bought a new stake in Danaher in the 3rd quarter valued at $442,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on DHR. Weiss Ratings reiterated a “hold (c-)” rating on shares of Danaher in a report on Wednesday, October 8th. JPMorgan Chase & Co. raised their price target on Danaher from $260.00 to $270.00 and gave the company an “overweight” rating in a research report on Wednesday, October 22nd. Rothschild & Co Redburn reissued a “neutral” rating and set a $220.00 price objective (down previously from $245.00) on shares of Danaher in a research report on Wednesday, October 8th. Robert W. Baird set a $247.00 target price on Danaher in a report on Wednesday, October 22nd. Finally, TD Cowen lifted their price target on Danaher from $250.00 to $260.00 and gave the stock a “buy” rating in a research report on Wednesday, October 22nd. Eighteen equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and a consensus price target of $243.39.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.